Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. - Wikidata - awgldk - TriplyDB

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

http://www.wikidata.org/entity/Q34736044

about

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs A genomewide association study of citalopram response in major depressive disorder A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity Genetic variants and risk of lung cancer in never smokers: a genome-wide association study Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis Data-driven methods to discover molecular determinants of serious adverse drug events.Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data.Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Circulating microRNAs involved in multiple sclerosis.Genome-wide association studies in pharmacogenomics: successes and lessons.Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon beta treatment.Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen.Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis.A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS.An integrated approach to design novel therapeutic interventions for demyelinating disorders Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.The conundrum of iron in multiple sclerosis--time for an individualised approach.Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients Nuanced roles of cytokines in three major human brain disorders.Pharmacogenomics in clinical practice and drug development.Tight junction proteins expression and modulation in immune cells and multiple sclerosis Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients Generating genome-scale candidate gene lists for pharmacogenomics.Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.IFN-beta pharmacogenomics in multiple sclerosis.Determinants of interferon β efficacy in patients with multiple sclerosis.Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.Integrative genomics strategies to elucidate the complexity of drug response.Pharmacogenomics in neurology: current state and future steps.Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.Multiple sclerosis: individualized disease susceptibility and therapy response.Clinical biomarkers in multiple sclerosis.

P2860

Q24630309-FE06D90F-86B1-4B2F-845A-B530AD6E9660 Q24656746-A1BE7784-8310-432A-A1DB-510A86184718 Q28257957-902EE9EE-2589-4C9C-900A-01C4D5650A5F Q28261215-9B976FEB-7514-4D77-AC64-65F9B490CFA7 Q28383607-0E717B36-0604-4BF4-962F-5829027469FD Q28943261-0BE52126-8838-439B-8EF1-5396CA461B2F Q33403734-FB7213F4-40CD-4FC3-86CB-65B6588E8F79 Q33796163-65F7E913-B4F0-416F-94AB-E07C4F1C788D Q34229109-721E118A-9B60-4E56-8880-87FA8011394D Q34246016-70E7D87D-A5C3-45CF-978A-759BC3A7ECC9 Q34415006-3909E88E-DF1F-4F18-BD74-19E32D2DFA19 Q34612307-BD1FBFA7-459F-4632-9608-C6E7FBEB3053 Q34712125-03F7DA39-B607-42F4-A3E8-D0714B99920C Q34777373-52C42F37-A1FD-41C3-91EF-B9B261DF7649 Q34812643-929B9DF5-2DCA-4274-9927-B60ECAB3419A Q35367901-1606111A-FA16-4870-9A61-CE188AAD4F65 Q35568496-B5375338-5CD5-42E4-9FBB-0AB09ADBF589 Q35847422-35859747-E553-4647-A671-0D7CEBF04B65 Q36001691-C15CF1ED-48D4-4DBB-A606-8AA598D7E91F Q36059972-77370B4A-0D44-44C2-B24D-2DFE804FBA5D Q36092690-B963D217-0EBF-4996-BFD6-C4B961D02822 Q36110218-2845FB65-FEFA-470D-8E87-3F6970C6C8C1 Q36562599-84884A88-D348-4748-BD4D-6574E5631B78 Q36955568-276771E1-B1DE-452F-9EA3-8339BB5FCE37 Q37284234-CBEF71F6-3BF0-40E3-95E8-948AE8E60A87 Q37294615-D83D7550-A33C-47C0-A839-27A8434DFF33 Q37294866-EDE3CF25-06C0-4699-A51A-2CD0231DA85C Q37307906-37EF9400-F0C1-4B3C-B71B-634DA353C3A5 Q37311193-B2D2E48A-E1F9-427B-B466-FB4B7C35324C Q37706612-6BAE0D8A-D794-4FA1-AE10-77B80648B0A8 Q37780222-F37ED453-3B84-4322-98E0-0DA431F1ABCE Q37848651-CEAAAF07-42A3-47BB-A8ED-74C21AEFC813 Q37859376-3DEED744-FB6C-44EA-AE57-29C1FF6FF540 Q37893991-7FD314FA-AAFB-46CA-940B-13F5D3A033B3 Q37961088-3B7BFAA2-2043-48CE-BF5D-49E863471CD5 Q37967607-C10496E8-5CFE-46A1-83E6-1EAD2BAB1AAE Q37990779-7CCC9F7B-4E67-48DA-A0CA-B8EF795D19C0 Q38050313-581432DD-8468-40DD-89EE-E43F7EC1D7A7 Q38079620-64818DE2-5F74-48FB-9C7E-E246BB07B0FA Q38088728-283ED001-C1D6-4223-A4F9-853371593E16

P2860

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

http://www.wikidata.org/entity/Q34736044

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@ast

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@en

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@nl

type

label

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@ast

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@en

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@nl

prefLabel

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@ast

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@en

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis.

@nl

P1433

Q34736044-E5D0D0C1-F900-44BF-BB3C-976BA94FF1E7

P1476

Q34736044-F5F9A4DD-DFC6-4A04-BCB8-B87BCB617E39

P2093

Q34736044-18BED993-17E2-4BE7-BAAE-5890382E678F

Q34736044-3EB4E890-DC84-4E4C-8D09-296DC1F5B88C

Q34736044-581767C0-3BDE-49AD-839D-16F97A5FAC9D

Q34736044-7DE90FC8-8F83-47BB-844E-7EE2065A1417

Q34736044-7FDFA355-5DF2-47E1-B23A-2BCF414FE3B9

Q34736044-A82FF1E9-82E7-4593-9108-5F9D0BB12C75

Q34736044-D311581C-BEA5-4914-8AF4-9234D25BBEEC

Q34736044-E4A42936-DF1E-497B-8F28-CB49427D042E

Q34736044-FB88986E-8225-4A94-A0B0-5E3AA0347C1D

P304

Q34736044-CC0C3401-3D75-45D5-AF2B-B145A39D69E3

P31

Q34736044-2E4D095B-FE39-444F-A412-D5C18647854C

P356

Q34736044-F77BFBD0-6C63-420F-A771-53A1836F7A70

P433

Q34736044-DA0F1514-9901-4B7D-A6DB-28CCE06CAE1D

P478

Q34736044-EA3AE324-0149-4613-AEC6-73EDAEEE50D4

P50

Q34736044-0A10EDD5-D77B-43CC-BA96-2FD7DEE39C65

Q34736044-8C8C3135-DF11-4402-B242-5B44076788F2

P577

Q34736044-344221C9-2E92-43D7-B214-60BBAE9D7104

P5875

Q34736044-DBEFD447-1D1E-4551-AAA6-15FE8895EF6E

P698

Q34736044-700F8249-8901-4617-8958-8DA6C263FBC7

P921

Q34736044-1631B661-3FFC-4C5A-8C0F-FE714548586B

Q34736044-D8DAEDD3-33E9-4A57-A446-8FDC36C765A4

P356

ARCHNEUROL.2008.47

P1433

P1476

Genome-wide pharmacogenomic an ...... therapy in multiple sclerosis

@en

P2093

David Brassat

http://www.w3.org/2001/XMLSchema#string

Esther Byun

http://www.w3.org/2001/XMLSchema#string

Joanne Wang

http://www.w3.org/2001/XMLSchema#string

Jorge R Oksenberg

http://www.w3.org/2001/XMLSchema#string

Lisa F Barcellos

http://www.w3.org/2001/XMLSchema#string

Manuel Comabella

http://www.w3.org/2001/XMLSchema#string

Oscar Fernández

http://www.w3.org/2001/XMLSchema#string

Sergio E Baranzini

http://www.w3.org/2001/XMLSchema#string

Stacy J Caillier

http://www.w3.org/2001/XMLSchema#string

P304

337-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2008.47

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Pablo Villoslada

Xavier Montalban

P577

2008-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5656673

http://www.w3.org/2001/XMLSchema#string

P698

18195134

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

multiple sclerosis